Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN-004 in Adult Allo-HCT Recipients
NCT04692181Phase 2Active, not recruiting
- Sponsor
- Theriva Biologics
- Start
- Feb 2021
- Primary completion
- Sep 2029
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ribaxamase in Clostridioides difficile infection (CDI), Acute Graft-Versus-Host Disease (aGvHD), sponsored by Theriva Biologics. Started Feb 2021; status: active, not recruiting.
02
Drugs
ribaxamase
03
Conditions
Clostridioides difficile infection (CDI)Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04692181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04692181.